Rezpegaldesleukin – Talk Bio

Actionable Insights Powered by AI

Nektar Digs Into Mid-Stage Data To Establish Alopecia Efficacy of Rezpeg

3 weeks ago talkbio0Tagged Alopecia, Autoimmune Diseases, Effectiveness, eli lilly, IL-2 pathway, mid-stage trial, Nektar Therapeutics, Phase 3 planning, REZOLVE-AA, Rezpeg, Rezpegaldesleukin, SALT score * *, Signal

Nektar Therapeutics; rezpegaldesleukin; Rezpeg; REZOLVE-AA; Phase 2b; alopecia areata; hair loss; SALT score; mid-stage trial; efficacy signal; Eli Lilly; IL-2 pathway; autoimmune disease; Phase 3 planning

Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical

7 months ago talkbio0Tagged analysts, Clinical Trials, Dermatitis, Atopic, Dupixent, EASI, Eczema, Lilly partnership, Nektar Therapeutics, Phase II B Trial, Rezpeg, Rezpegaldesleukin, Score, Skepticism

Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership